We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

32 hedge funds and large institutions have $3.08M invested in Acorda Therapeutics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

3% more funds holding

Funds holding: 31 → 32 (+1)

43% less capital invested

Capital invested by funds: $5.42M → $3.08M (-$2.34M)

Holders
32
Holders Change
+1
Holders Change %
+3.23%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
10
Reduced
5
Closed
8
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
-$47K

Top Buyers

1
DKCM
Davidson Kempner Capital Management
New York
+$2.13M
2
CCA
Canyon Capital Advisors
Texas
+$484K
3
Millennium Management
Millennium Management
New York
+$240K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$191K
5
Renaissance Technologies
Renaissance Technologies
New York
+$173K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$747K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$163K
3
BCM
Bridgeway Capital Management
Texas
-$127K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$32K
5
BlackRock
BlackRock
New York
-$23.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$1.11M +$2.13M +119,783 New
CCA
2
Canyon Capital Advisors
Texas
$556K +$484K +27,247 +84%
Renaissance Technologies
3
Renaissance Technologies
New York
$420K +$173K +9,705 +27%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$318K +$191K +10,747 +46%
Millennium Management
5
Millennium Management
New York
$145K +$240K +13,529 +661%
Vanguard Group
6
Vanguard Group
Pennsylvania
$73K -$163K -9,174 -54%
VF
7
Virtu Financial
New York
$68K +$129K +7,266 New
BlackRock
8
BlackRock
New York
$66K -$23.1K -1,298 -16%
SC
9
Saltoro Capital
Texas
$51K +$83.5K +4,699 +633%
BCM
10
Bridgeway Capital Management
Texas
$47K -$127K -7,120 -58%
Wells Fargo
11
Wells Fargo
California
$35K +$22K +1,240 +50%
Prudential Financial
12
Prudential Financial
New Jersey
$28K +$53.5K +3,010 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$21K – – –
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$21K +$40.8K +2,294 New
HF
15
HRT Financial
New York
$18K +$34.9K +1,966 New
State Street
16
State Street
Massachusetts
$15K – – –
UAS
17
United Asset Strategies
New York
$13K – – –
UBS Group
18
UBS Group
Switzerland
$13K +$23K +1,294 +918%
TRCT
19
Tower Research Capital (TRC)
New York
$13K +$23.7K +1,333 +4,597%
TSS
20
Two Sigma Securities
New York
$13K +$24.6K +1,385 New
Northern Trust
21
Northern Trust
Illinois
$12K -$444 -25 -2%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$7K – – –
E
23
Ergoteles
New York
$6K +$11.8K +665 New
Verition Fund Management
24
Verition Fund Management
Connecticut
$6K +$12.1K +682 New
SQA
25
Simon Quick Advisors
New Jersey
$6K +$12.6K +711 New
1
2

ACOR Hedge Fund Activity: Q2 2022 in Review

32 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2022, worth a combined $3.08M — down 43% from $5.42M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ACOR positions and 8 closed out — a net gain of 2 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was Davidson Kempner Capital Management, opening a new position worth an estimated $2.13M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $747K sold.

  • 32 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2022, up from 31 in Q1 2022.
  • Funds reported $3.08M of Acorda Therapeutics stock for Q2 2022, down 43% quarter-over-quarter.
  • 10 funds opened new Acorda Therapeutics positions in Q2 2022 and 8 closed out, a net change of +2 holders.
  • The largest Acorda Therapeutics buyer in Q2 2022 was Davidson Kempner Capital Management, an estimated $2.13M added.
  • The largest Acorda Therapeutics seller in Q2 2022 was Point72 Asset Management, an estimated $747K sold.

Based on aggregated 13F filings for Q2 2022.